tiprankstipranks
Shoreline to acquire Editas’ iNK cell franchise, related gene editing tech
The Fly

Shoreline to acquire Editas’ iNK cell franchise, related gene editing tech

Editas Medicine announced that it has entered into a definitive agreement with Shoreline Biosciences for Shoreline to license Editas Medicine’s proprietary SLEEK and AsCas12a gene editing technologies and acquire Editas Medicine’s preclinical gene edited induced pluripotent stem cell derived natural killer cell programs and related manufacturing technologies. Shoreline Biosciences is a private biopharmaceutical company developing next-generation cellular immunotherapies based on iPSCs utilizing proprietary iNK and macrophage platforms. Under the terms of the agreement, Shoreline will obtain an exclusive license to Editas Medicine’s interest in SLEEK gene editing knock-in technology for use in Shoreline’s iNK platform and for oncology in its iMACs platform, and on a non-exclusive basis for iMACs in other indications. Shoreline will also receive a non-exclusive license for the use of Editas Medicine’s engineered AsCas12a enzyme. As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. The acquisition of the Company’s wholly owned oncology assets by Shoreline is part of Editas Medicine’s strategic portfolio reprioritization, including its focus on the development of in vivo gene edited medicines. Shoreline will pay Editas Medicine an upfront payment at the close of the transaction. Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies. Evercore Group LLC served as financial advisor to Editas Medicine on the transaction.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on EDIT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles